CTSO CytoSorbents Corp: Likuiditas cepet

The price action of Cytosorbents (CTSO) reflects the dynamics of a company facing physician conservatism and intense pressure from traditional players in the blood purification sector, while the liquidity ratio stands at 0.48. The business relies on its own polymer production, outsourcing the manufacturing of housings and delivery to external partners. A key advantage is the patent-protected CytoSorb technology, which has gained recognition in Europe.

The quick ratio assesses the ability of Cytosorbents (CTSO) to meet its short-term obligations using its most liquid assets, excluding illiquid inventory. By analyzing the critical liquidity trend, an investor can evaluate the balance of cash and accounts receivable, which is fundamentally important for Cytosorbents due to the inertia in implementing blood purification systems and the conservatism of physicians, both of which slow down inventory turnover.